EGFR and neoplasm: In the treatment of NSCLC cases that harbor epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, can block the survival signals that are mediated by this driver oncogene and can induce marked tumor regression [14].